ClinicalTrials.gg
TerminatedNCT04952753daNIS-3Updated Nov 16, 2026Results posted

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

A Phase 2 interventional study of NIS793 and Bevacizumab in Metastatic Colorectal Cancer, sponsored by Novartis Pharmaceuticals. Terminated at 55 sites in 17 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated early due to the halt of NIS793 treatment and urgent safety measures issued in July and August 2023, respectively, as continued evaluation of Standard of Care alone will not support the trial's purpose.
Updated Nov 16, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Colorectal Neoplasms by Novartis — 3 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · Novartis.

Enrollment
6th of 30
202 · median 123
Started
2021
with 1 other
Phase 2
4 of 30
none open now
Registered
23rd of 30
by date

Among the 30 studies in Colorectal Neoplasms by Novartis, this one is the 6th largest by enrollment, is one of 2 that started in 2021, is one of 4 in phase 2, and was the 23rd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 30 studies in Colorectal Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Colorectal Neoplasms by Novartis, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy versus SOC anti-cancer therapy for the second-line treatment of mCRC.

This study aimed to explore whether different mechanisms of action could reverse resistance and improve responsiveness to the then-considered SOC anti-cancer therapy in the second-line metastatic colorectal cancer (mCRC) setting.

Read the detailed description

This was an open-label, multi-center, Phase II platform study with both control and investigational arms. Each investigational arm included a Safety Run-In (SRI) phase, followed by an Expansion Part. In the control arm, the standard of care (SoC) anti-cancer therapy consisted of bevacizumab in combination with either modified FOLFOX6 (mFOLFOX6: folinic acid, fluorouracil, and oxaliplatin) or FOLFIRI (folinic acid, fluorouracil, and irinotecan).

On July 31, 2023, administration of NIS793 and tislelizumab was halted, and this action was subsequently classified as an Urgent Safety Measure on August 3, 2023, due to an unfavorable benefit/risk profile observed in participants with metastatic colorectal cancer (mCRC).

Each investigational arm included a combination of an investigational drug and the standard of care anti-cancer therapy:

  • Investigational arm #1 included NIS793 in combination with standard of care anti-cancer therapy.
  • Investigational arm #2 included NIS793 in combination with tislelizumab and standard of care anti-cancer therapy.

Safety Run-In Part:

The Safety Run-In (SRI) phase was initiated to confirm the recommended phase 2 dose (RP2D) of the investigational drug(s) in combination with standard of care anti-cancer therapy.

  • For Investigational arm #1, the SRI for both FOLFIRI and mFOLFOX6 regimens was fully enrolled. The RP2D for SRI arm #1 (both FOLFIRI and mFOLFOX6) was declared, and the Expansion Part for arm #1 (both FOLFIRI and mFOLFOX6) was opened and fully enrolled.

    \~ Duration: Each SRI part enrolled up to approximately 20 participants per regimen, with the SRI phase typically lasting until at least 12 evaluable participants completed one 28-day treatment cycle (4 weeks) per regimen.

  • For Investigational arm #2, the SRI for FOLFIRI was fully enrolled, the RP2D was declared, and enrollment for the Expansion Part of arm #2 (FOLFIRI) was ongoing at the time of study termination. The SRI for mFOLFOX6 was also fully enrolled. However, the Data Monitoring Committee (DMC) recommended halting NIS793 and holding tislelizumab treatment on July 31, 2023, and permanently discontinuing tislelizumab on August 3, 2023. Therefore, even after completion of the SRI for arm #2 (mFOLFOX6), the decision was made not to proceed with preparation for a dose confirmation meeting for this group. As a result, no data summaries were produced for investigational arm #2 (mFOLFOX6).

Expansion Part:

The decision to open the Expansion Part of the study was based on dose confirmation of the investigational drug, with available safety, relevant pharmacokinetic (PK), and other relevant clinical and laboratory data from the SRI phase. The Expansion Part ran independently for each standard of care anti-cancer therapy (mFOLFOX6 or FOLFIRI with bevacizumab).

\~ Duration: Each Expansion Part was planned to enroll approximately 75 participants per investigational arm and per regimen, with treatment cycles of 28 days each. Participants continued in the Expansion Part until unacceptable toxicity, disease progression, withdrawal of consent, or other protocol-specified discontinuation criteria were met.

After NIS793 and tislelizumab were permanently discontinued, participants were allowed to continue with standard of care therapy as assessed by the Investigator. No additional treatment arms were introduced during the study.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • NIS793
  • metastatic colorectal cancer
  • colorectal cancer
  • transforming growth factor βeta (TGF-β)
  • anti PD-1 monoclonal antibody
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  • Participants aged 18 or older with or cytologically confirmed (by local laboratory and local clinical guidelines) colorectal adenocarcinoma that is not amenable to potentially curative surgery in the opinion of the Investigator and progressed on or within 6 months after the last dose of one prior line of systemic anti-cancer therapy administered for metastatic disease.
  • Presence of at least one assessed by CT and/or MRI according to 1.1.
  • Performance Status 0 or 1.
  • Adequate organ function (assessed by central laboratory for eligibility).

Key Exclusion criteria:

  • Previously administered systemic immunotherapy (e.g. , anti-PD-L1/-L2, anti-CTLA-4 antibody) or TGF-β targeted therapies.
  • Microsatellite instability-high/mismatch repair-deficient (mandatory, locally performed), BRAFV600 mutation positive CRC.
  • Known complete or partial DPD enzyme deficiency.
  • For participants treated with irinotecan: Known history or clinical evidence of reduced UGT1A1 activity.
  • Participants who have not recovered from a major surgery performed prior to start of study treatment or have had a major surgery within 4 weeks prior to start of study treatment.
  • Impaired cardiac function or cardio-vascular disease.
  • Participants with conditions associated with or history of significant bleeding.
  • Stroke or , or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 3 months before start of study treatment.
  • Active, known, or suspected disease or a documented history of autoimmune disease
  • Pregnant or breast-feeding women, and women of , unless willing to use highly effective methods during treatment and after stopping study treatments as required.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Safety run-in: NIS793+SOC (Investigational arm 1)

    Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 to confirm the RP2D of NIS793

    Drug: NIS793 · Drug: Bevacizumab · Drug: Modified FOLFOX6 · Drug: FOLFIRI

  • Experimental
    Expansion: NIS793+SOC (Investigational arm 1)

    Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 at the RP2D defined in the safety run-in

    Drug: NIS793 · Drug: Bevacizumab · Drug: Modified FOLFOX6 · Drug: FOLFIRI

  • Active comparator
    Expansion: SOC (control arm)

    Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI)

    Drug: Bevacizumab · Drug: Modified FOLFOX6 · Drug: FOLFIRI

  • Experimental
    Safety run-in: NIS793+Tislelizumab+SOC (Investigational arm 2)

    Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI), NIS793, and tislelizumab to confirm the RP2D of NIS793

    Drug: NIS793 · Drug: Bevacizumab · Drug: Modified FOLFOX6 · Drug: FOLFIRI · Drug: Tislelizumab

  • Experimental
    Expansion: NIS793+Tislelizumab+SOC (Investigational arm 2)

    Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI), NIS793, and tislelizumab at the RP2D for NIS793 defined in the safety run-in

    Drug: NIS793 · Drug: Bevacizumab · Drug: Modified FOLFOX6 · Drug: FOLFIRI · Drug: Tislelizumab

Interventions

  • DrugNisevokitugStudies of NisevokitugNisevokitug pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Investigational drug NIS793 was administered intravenously (IV) at the dose and schedule determined in the safety run-in part

  • Bevacizumab was administered intravenously (IV)

  • DrugModified FOLFOX6

    5-fluorouracil \[administered as a continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]

    Also known as: 5FU+Leucovorin+Oxaliplatin

  • DrugFOLFIRI

    5-fluorouracil \[administered as a continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]

    Also known as: 5FU+Leucovorin+Irinotecan

  • Investigational drug tislelizumab was administered intravenously (IV)

    Also known as: VDT482

06

What researchers measure

Primary outcomes

  1. (Safety run-in Part) Number of Participants With Dose Limiting Toxicities (DLTs) During the First Cycle (4 Weeks) of Treatment.

    The primary endpoint for the Safety Run-In part was the incidence of dose-limiting toxicities (DLT) during the first 28 days of treatment with investigational drug(s) (NIS793 with or without tislelizumab) and standard of care anti-cancer therapy. Dose tolerability decisions were based on all safety data and a Bayesian Logistic Regression Model (BLRM) using Escalation with Overdose Control (EWOC) criteria. Dose confirmation required at least six evaluable participants, fulfillment of EWOC criteria, and recommendation by Novartis and investigators after reviewing clinical, pharmacokinetic, and laboratory data.

    Time frame: Up to 4 weeks

  2. (Expansion Part) Progression-free Survival (PFS) by Investigator Assessment Per RECIST 1.1

    PFS was defined as the time from the date of enrollment (run-in part) or randomization (randomized part) to the date of the first documented progression based on investigator assessment and according to RECIST 1.1 or death due to any cause

    Time frame: From randomization up to disease progression or death, assessed up to approximately 11 months

Secondary outcomes

  1. (Safety run-in Part) Percentage of Participants With Adverse Events (AEs)

    Percentage of participants who experienced AEs and SAEs, including changes in laboratory parameters, vital signs, body weight, and cardiac assessments

    Time frame: Through Safety Run-in completion, an average of 6 months

  2. (Safety Run-In) Percentage of Participants With Dose Interruptions and Dose Reductions of Investigational Drug

    Tolerability was measured by the percentage of subjects who had dose adjustments (interruptions or reductions) of investigational drug (NIS793, NIS793 + tislelizumab)

    Time frame: Up to approximately 7 months

  3. (Safety Run-In) Dose Intensity of Investigational Drug

    Tolerability was measured by the dose intensity of the investigational drug (e.g., NIS793, NIS793 + tislelizumab). Dose intensity was computed as the ratio of the actual cumulative dose received to the actual duration of exposure.

    Time frame: Up to approximately 7 months

  4. (Safety run-in Part) PFS by Investigator Assessment Per RECIST 1.1

    PFS was defined as the time from the date of enrollment to the date of the first documented progression based on investigator assessment and according to RECIST 1.1 or death due to any cause

    Time frame: From enrollment up to disease progression or death, assessed up to approximately 7 months

  5. (Safety run-in Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.1

    ORR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator assessment and according to RECIST 1.1

    Time frame: Up to approximately 7 months

  6. (Safety run-in Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.1

    DCR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD), as per investigator assessment and according to RECIST 1.1

    Time frame: Up to approximately 7 months

  7. (Safety run-in Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.1

    DOR was defined as the duration of time between the date of the first documented response (CR or PR) and the date of first documented progression or death due to any cause

    Time frame: From first documented response up to disease progression or death, assessed up to approximately 7 months

  8. (Safety run-in Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1

    TTR was defined as the duration of time between the date of enrollment and the date of the first documented response of either CR or PR

    Time frame: From enrollment up to first documented response, assessed up to approximately 7 months

  9. (Safety run-in Part) Overall Survival (OS)

    OS was defined as the time from the date of enrollment to the date of death due to any cause

    Time frame: Up to two years

  10. (Safety run-in Part) Maximum Concentration (Cmax) of NIS793 and Tislelizumab

    Blood samples were collected at indicated time-points for analysis of Cmax of NIS793 and tislelizumab.

    Time frame: Cycle 1 Day 1, Cycle 3 Day 1 (1 cycle = 28 days).

  11. (Safety run-in Part) Trough Concentration (Ctrough) of NIS793 and Tislelizumab

    Blood samples were collected at indicated time-points for analysis of Ctrough of NIS793 and tislelizumab

    Time frame: Cycle 1 Day 15, Cycle 3 Day 1, Cycle 3 Day 15, Cycle 6 Day 1 (1 cycle = 28 days)

  12. (Safety run-in Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) at Baseline

    Prevalence of NIS793 and Tislelizumab Antidrug antibodies (ADA) at baseline was defined as the proportion of participants who had an ADA positive result at baseline

    Time frame: Baseline

  13. (Safety run-in Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on Treatment

    Incidence of NIS793 and Tislelizumab Antidrug antibodies (ADA) on treatment was defined as the proportion of participants who were treatment-induced ADA positive (post-baseline ADA positive with an ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with a titer that was at least the fold titer change greater than the ADA-positive baseline titer)

    Time frame: From the date of first study drug intake up to approximately 7 months

  14. (Expansion Part) Percentage of Participants With Adverse Events (AEs)

    The percentage of participants who experienced AEs and SAEs, including changes in laboratory parameters, vital signs, body weight, and cardiac assessments

    Time frame: Through Expansion completion, an average of 8 months

  15. (Expansion Part) Percentage of Participants With Dose Interruptions and Dose Reductions of Investigational Drug

    Tolerability was measured by the percentage of subjects who had dose adjustments (interruptions) of the investigational drug (e.g., NIS793, NIS793 + tislelizumab)

    Time frame: Up to approximately 11 months

  16. (Expansion Part) Dose Intensity of Investigational Drug

    Tolerability was measured by the dose intensity of the investigational drug (e.g., NIS793, NIS793 + Tislelizumab). Dose intensity was computed as the ratio of the actual cumulative dose received to the actual duration of exposure.

    Time frame: Up to approximately 11 months

  17. (Expansion Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.1

    ORR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator assessment and according to RECIST 1.1

    Time frame: Up to approximately 11 months

  18. (Expansion Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.1

    DCR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD), as per investigator assessment and according to RECIST 1.1

    Time frame: Up to approximately 11 months

  19. (Expansion Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.1

    DOR was defined as the duration of time between the date of the first documented response (CR or PR) and the date of first documented progression or death due to any cause

    Time frame: From first documented response up to disease progression or death, assessed up to approximately 11 months

  20. (Expansion Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1

    TTR was defined as the duration of time between the date of enrollment and the date of first documented response of either CR or PR

    Time frame: From enrollment up to first documented response, assessed up to approximately 11 months

  21. (Expansion Part) Overall Survival (OS)

    OS was defined as the time from the date of enrollment to the date of death due to any cause

    Time frame: Up to two years

  22. (Expansion Part) Maximum Concentration (Cmax) of NIS793 and Tislelizumab

    Blood samples were collected at indicated time-points for analysis of Cmax of NIS793 and tislelizumab

    Time frame: Cycle 1 Day 1, Cycle 3 Day 1 (NIS793 only) (1 cycle = 28 days)

  23. (Expansion Part) Trough Concentration (Ctrough) of NIS793 and Tislelizumab

    Blood samples were collected at indicated time-points for analysis of Ctrough of NIS793 and tislelizumab

    Time frame: Cycle 1 Day 15 (NIS793 only), Cycle 2 Day (tislelizumab only), Cycle 3 Day 1, Cycle 3 Day 15 (NIS793 only), Cycle 4 Day (tislelizumab only), Cycle 6 Day 1 (NIS793 only) (1 cycle = 28 days)

  24. (Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) at Baseline

    Prevalence of NIS793 and Tislelizumab Antidrug antibodies (ADA) at baseline was defined as the proportion of participants who had an ADA positive result at baseline

    Time frame: Baseline

  25. (Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on Treatment

    Incidence of NIS793 and Tislelizumab Antidrug antibodies (ADA) on treatment was defined as the proportion of participants who were treatment-induced ADA positive (post-baseline ADA positive with an ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with a titer that was at least the fold titer change greater than the ADA-positive baseline titer)

    Time frame: From the date of first study drug intake up to approximately 11 months

07

Results

Posted Nov 16, 2026

Participant flow

The study was conducted globally across 17 countries: Australia (3 centers), Belgium (3 centers), Canada (4 centers), Switzerland (1 center), Czech Republic (3 centers), Germany (8 centers), Spain (5 centers), France (3 centers), United Kingdom (3 centers), Hong Kong (2 centers), Israel (2 centers), Italy (3 centers), Japan (5 centers), Korea (1 center), Singapore (1 center), Taiwan (2 centers), and USA (7 centers).

Participant flow — Overall Study
MilestoneSafety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI)Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6)Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI)Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Expansion (Control Arm): SoC (FOLFIRI)Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Expansion (Control Arm): SoC (mFOLFOX6)
Started139108672946137
Safety set139108652946157
Pharmacokinetic analysis sets (pas) for nis793 (nis-pas)1394260180120
Pharmacokinetic analysis sets (pas) tislelizumab (tsl-pas)0094019000
Immunogenicity (ig) prevalence set for nis7931397665210150
Immunogenicity (ig) prevalence set for tislelizumab00108028000
Immunogenicity incidence set - nis793108205550120
Immunogenicity incidence set - tislelizumab0064020000
Completed000000000
Not completed139108672946137
Withdrew: Progressive disease10695461526105
Withdrew: Physician decision200193410
Withdrew: Adverse event111141000
Withdrew: Withdrawal by subject020144722
Withdrew: Study terminated by sponsor000036700
Withdrew: Death000010100
Withdrew: Lost to follow-up000000100

Outcome measures

Primary(Safety run-in Part) Number of Participants With Dose Limiting Toxicities (DLTs) During the First Cycle (4 Weeks) of Treatment.

The primary endpoint for the Safety Run-In part was the incidence of dose-limiting toxicities (DLT) during the first 28 days of treatment with investigational drug(s) (NIS793 with or without tislelizumab) and standard of care anti-cancer therapy. Dose tolerability decisions were based on all safety data and a Bayesian Logistic Regression Model (BLRM) using Escalation with Overdose Control (EWOC) criteria. Dose confirmation required at least six evaluable participants, fulfillment of EWOC criteria, and recommendation by Novartis and investigators after reviewing clinical, pharmacokinetic, and laboratory data.

Time frame:
Up to 4 weeks
Reported as:
Count of participants · Participants
(Safety run-in Part) Number of Participants With Dose Limiting Toxicities (DLTs) During the First Cycle (4 Weeks) of Treatment.
ParticipantsSafety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI)Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6)
(Safety run-in Part) Number of Participants With Dose Limiting Toxicities (DLTs) During the First Cycle (4 Weeks) of Treatment.1110
Primary(Expansion Part) Progression-free Survival (PFS) by Investigator Assessment Per RECIST 1.1

PFS was defined as the time from the date of enrollment (run-in part) or randomization (randomized part) to the date of the first documented progression based on investigator assessment and according to RECIST 1.1 or death due to any cause

Time frame:
From randomization up to disease progression or death, assessed up to approximately 11 months
Reported as:
Median · Months
(Expansion Part) Progression-free Survival (PFS) by Investigator Assessment Per RECIST 1.1
MonthsExpansion (Investigational Arm 1): NIS793+SoCExpansion (Investigational Arm 2): NIS793+TISLE+SoCExpansion (Control Arm): SoC
(Expansion Part) Progression-free Survival (PFS) by Investigator Assessment Per RECIST 1.15.1 (3.6 to 5.7)3.7 (2.2 to 5.6)7.4 (5.5 to 9.4)
Secondary(Safety run-in Part) Percentage of Participants With Adverse Events (AEs)

Percentage of participants who experienced AEs and SAEs, including changes in laboratory parameters, vital signs, body weight, and cardiac assessments

Time frame:
Through Safety Run-in completion, an average of 6 months
Reported as:
Count of participants · Participants
(Safety run-in Part) Percentage of Participants With Adverse Events (AEs)
ParticipantsSafety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI)Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6)
Adverse Events (AEs)139108
Serious Adverse Events (SAEs)6665
Fatal SAEs0000
AEs leading to discontinuation5312
AEs leading to dose adjustment/interruption12797
AEs requiring additional therapy139108
Secondary(Safety Run-In) Percentage of Participants With Dose Interruptions and Dose Reductions of Investigational Drug

Tolerability was measured by the percentage of subjects who had dose adjustments (interruptions or reductions) of investigational drug (NIS793, NIS793 + tislelizumab)

Time frame:
Up to approximately 7 months
Reported as:
Count of participants · Participants
(Safety Run-In) Percentage of Participants With Dose Interruptions and Dose Reductions of Investigational Drug
ParticipantsSafety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI)Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6)
NIS793: Participants with at least one dose reduction1000
NIS793: Participants with at least one dose interruption8695
Tislelizumab: Participants with at least one dose reduction0000
Tislelizumab: Participants with at least one dose interruption0052
Secondary(Safety Run-In) Dose Intensity of Investigational Drug

Tolerability was measured by the dose intensity of the investigational drug (e.g., NIS793, NIS793 + tislelizumab). Dose intensity was computed as the ratio of the actual cumulative dose received to the actual duration of exposure.

Time frame:
Up to approximately 7 months
Reported as:
Mean · mg/cycle
(Safety Run-In) Dose Intensity of Investigational Drug
mg/cycleSafety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI)Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6)
NIS7934171.2 ± 664.813792.7 ± 426.973550.5 ± 387.833703.4 ± 627.94
Tislelizumab——273.1 ± 28.72277.9 ± 45.58
Secondary(Safety run-in Part) PFS by Investigator Assessment Per RECIST 1.1

PFS was defined as the time from the date of enrollment to the date of the first documented progression based on investigator assessment and according to RECIST 1.1 or death due to any cause

Time frame:
From enrollment up to disease progression or death, assessed up to approximately 7 months
Reported as:
Median · Months
(Safety run-in Part) PFS by Investigator Assessment Per RECIST 1.1
MonthsSafety Run-In (Investigational Arm 1): NIS793+SoCSafety Run-In (Investigational Arm 2): NIS793+TISLE+SoC
(Safety run-in Part) PFS by Investigator Assessment Per RECIST 1.13.6 (1.9 to 7.3)2.1 (1.8 to 4.3)
Secondary(Safety run-in Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.1

ORR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator assessment and according to RECIST 1.1

Time frame:
Up to approximately 7 months
Reported as:
Number · Percentage of Responders
(Safety run-in Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.1
Percentage of RespondersSafety Run-In (Investigational Arm 1): NIS793+SoCSafety Run-In (Investigational Arm 2): NIS793+TISLE+SoC
(Safety run-in Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.14.5 (0.1 to 22.8)0 (NA to NA)
Secondary(Safety run-in Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.1

DCR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD), as per investigator assessment and according to RECIST 1.1

Time frame:
Up to approximately 7 months
Reported as:
Number · Percentage of Responders
(Safety run-in Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.1
Percentage of RespondersSafety Run-In (Investigational Arm 1): NIS793+SoCSafety Run-In (Investigational Arm 2): NIS793+TISLE+SoC
(Safety run-in Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.163.6 (40.7 to 82.8)44.4 (21.5 to 69.2)
Secondary(Safety run-in Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.1

DOR was defined as the duration of time between the date of the first documented response (CR or PR) and the date of first documented progression or death due to any cause

Time frame:
From first documented response up to disease progression or death, assessed up to approximately 7 months
Reported as:
Median · Months
(Safety run-in Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.1
MonthsSafety Run-In (Investigational Arm 1): NIS793+SoCSafety Run-In (Investigational Arm 2): NIS793+TISLE+SoC
(Safety run-in Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.19.4 (NA to NA)NA (NA to NA)
Secondary(Safety run-in Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1

TTR was defined as the duration of time between the date of enrollment and the date of the first documented response of either CR or PR

Time frame:
From enrollment up to first documented response, assessed up to approximately 7 months
Reported as:
Median · Months
(Safety run-in Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1
MonthsSafety Run-In (Investigational Arm 1): NIS793+SoCSafety Run-In (Investigational Arm 2): NIS793+TISLE+SoC
(Safety run-in Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1NA (NA to NA)NA (NA to NA)
Secondary(Safety run-in Part) Overall Survival (OS)

OS was defined as the time from the date of enrollment to the date of death due to any cause

Time frame:
Up to two years
Reported as:
Median · Months
(Safety run-in Part) Overall Survival (OS)
MonthsSafety Run-In (Investigational Arm 1): NIS793+SoCSafety Run-In (Investigational Arm 2): NIS793+TISLE+SoC
(Safety run-in Part) Overall Survival (OS)10.2 (5.8 to 20.8)11.0 (6.2 to 15.7)
Secondary(Safety run-in Part) Maximum Concentration (Cmax) of NIS793 and Tislelizumab

Blood samples were collected at indicated time-points for analysis of Cmax of NIS793 and tislelizumab.

Time frame:
Cycle 1 Day 1, Cycle 3 Day 1 (1 cycle = 28 days).
Reported as:
Mean · ng/mL
(Safety run-in Part) Maximum Concentration (Cmax) of NIS793 and Tislelizumab
ng/mLSafety Run-In (Investigational Arm 1): NIS793+SoCSafety Run-In (Investigational Arm 2): NIS793+TISLE+SoC
NIS793: Cycle 1 Day 1556000 ± 161000663000 ± NA
NIS793: Cycle 3 Day 1967000 ± 2850001130000 ± NA
tislelizumab: Cycle 1 Day 1—71800 ± 10300
tislelizumab: Cycle 3 Day 1—90300 ± 11100
Secondary(Safety run-in Part) Trough Concentration (Ctrough) of NIS793 and Tislelizumab

Blood samples were collected at indicated time-points for analysis of Ctrough of NIS793 and tislelizumab

Time frame:
Cycle 1 Day 15, Cycle 3 Day 1, Cycle 3 Day 15, Cycle 6 Day 1 (1 cycle = 28 days)
Reported as:
Mean · ng/mL
(Safety run-in Part) Trough Concentration (Ctrough) of NIS793 and Tislelizumab
ng/mLSafety Run-In (Investigational Arm 1): NIS793+SoCSafety Run-In (Investigational Arm 2): NIS793+TISLE+SoC
NIS793: Cycle 1 Day 15164000 ± 59800173000 ± 18700
NIS793: Cycle 3 Day 1406000 ± 178000284000 ± 136000
NIS793: Cycle 3 Day 15439000 ± 165000273000 ± 12700
NIS793: Cycle 6 Day 1699000 ± 324000—
tislelizumab: Cycle 1 Day 15—28600 ± 40300
tislelizumab: Cycle 3 Day 1—21500 ± 8710
tislelizumab: Cycle 3 Day 15—23600 ± 3700
tislelizumab: Cycle 6 Day 1—48800 ± 30300
Secondary(Safety run-in Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) at Baseline

Prevalence of NIS793 and Tislelizumab Antidrug antibodies (ADA) at baseline was defined as the proportion of participants who had an ADA positive result at baseline

Time frame:
Baseline
Reported as:
Count of participants · Participants
(Safety run-in Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) at Baseline
ParticipantsSafety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI and mFOLFOX6)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI and mFOLFOX6)
NIS793: ADA-positive (i.e. ADA prevalence)00
Tislelizumab: ADA-positive (i.e. ADA prevalence)02
Secondary(Safety run-in Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on Treatment

Incidence of NIS793 and Tislelizumab Antidrug antibodies (ADA) on treatment was defined as the proportion of participants who were treatment-induced ADA positive (post-baseline ADA positive with an ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with a titer that was at least the fold titer change greater than the ADA-positive baseline titer)

Time frame:
From the date of first study drug intake up to approximately 7 months
Reported as:
Count of participants · Participants
(Safety run-in Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on Treatment
ParticipantsSafety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI and mFOLFOX6)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI and mFOLFOX6)
NIS793: Treatment-induced ADA-positive00
NIS793: Treatment-boosted ADA-positive00
Tislelizumab: Treatment-induced ADA-positive02
Tislelizumab: Treatment-boosted ADA-positive00
Secondary(Expansion Part) Percentage of Participants With Adverse Events (AEs)

The percentage of participants who experienced AEs and SAEs, including changes in laboratory parameters, vital signs, body weight, and cardiac assessments

Time frame:
Through Expansion completion, an average of 8 months
Reported as:
Count of participants · Participants
(Expansion Part) Percentage of Participants With Adverse Events (AEs)
ParticipantsExpansion (Investigational Arm 1): NIS793+SoC (FOLFIRI)Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Expansion (Control Arm): SoC (FOLFIRI)Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Expansion (Control Arm): SoC (mFOLFOX6)
Adverse Events (AEs)652645147
Serious Adverse Events (SAEs)3291463
Fatal SAEs00000
AEs leading to discontinuation195953
AEs leading to dose adjustment/interruption47173495
AEs requiring additional therapy602639146
Secondary(Expansion Part) Percentage of Participants With Dose Interruptions and Dose Reductions of Investigational Drug

Tolerability was measured by the percentage of subjects who had dose adjustments (interruptions) of the investigational drug (e.g., NIS793, NIS793 + tislelizumab)

Time frame:
Up to approximately 11 months
Reported as:
Count of participants · Participants
(Expansion Part) Percentage of Participants With Dose Interruptions and Dose Reductions of Investigational Drug
ParticipantsExpansion (Investigational Arm 1): NIS793+SoC (FOLFIRI)Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)
NIS793: Participants with at least one dose reduction100
NIS793: Participants with at least one dose interruption40810
Tislelizumab: Participants with at least one dose reduction000
Tislelizumab: Participants with at least one dose interruption006
Secondary(Expansion Part) Dose Intensity of Investigational Drug

Tolerability was measured by the dose intensity of the investigational drug (e.g., NIS793, NIS793 + Tislelizumab). Dose intensity was computed as the ratio of the actual cumulative dose received to the actual duration of exposure.

Time frame:
Up to approximately 11 months
Reported as:
Mean · mg/cycle
(Expansion Part) Dose Intensity of Investigational Drug
mg/cycleExpansion (Investigational Arm 1): NIS793+SoC (FOLFIRI)Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)
NIS7933865.2 ± 591.353786.2 ± 437.933982.1 ± 393.43
Tislelizumab——290.8 ± 19.39
Secondary(Expansion Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.1

ORR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator assessment and according to RECIST 1.1

Time frame:
Up to approximately 11 months
Reported as:
Number · Percentage of Responders
(Expansion Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.1
Percentage of RespondersExpansion (Investigational Arm 1): NIS793+SoCExpansion (Investigational Arm 2): NIS793+TISLE+SoCExpansion (Control Arm): SoC
(Expansion Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.18.8 (3.6 to 17.2)13.8 (3.9 to 31.7)15.1 (6.7 to 27.6)
Secondary(Expansion Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.1

DCR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD), as per investigator assessment and according to RECIST 1.1

Time frame:
Up to approximately 11 months
Reported as:
Number · Percentage of Responders
(Expansion Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.1
Percentage of RespondersExpansion (Investigational Arm 1): NIS793+SoCExpansion (Investigational Arm 2): NIS793+TISLE+SoCExpansion (Control Arm): SoC
(Expansion Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.166.3 (54.8 to 76.4)65.5 (45.7 to 82.1)79.2 (65.9 to 89.2)
Secondary(Expansion Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.1

DOR was defined as the duration of time between the date of the first documented response (CR or PR) and the date of first documented progression or death due to any cause

Time frame:
From first documented response up to disease progression or death, assessed up to approximately 11 months
Reported as:
Median · Months
(Expansion Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.1
MonthsExpansion (Investigational Arm 1): NIS793+SoCExpansion (Investigational Arm 2): NIS793+TISLE+SoCExpansion (Control Arm): SoC
(Expansion Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.19.5 (4.0 to NA)NA (NA to NA)11.1 (3.8 to NA)
Secondary(Expansion Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1

TTR was defined as the duration of time between the date of enrollment and the date of first documented response of either CR or PR

Time frame:
From enrollment up to first documented response, assessed up to approximately 11 months
Reported as:
Median · Months
(Expansion Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1
MonthsExpansion (Investigational Arm 1): NIS793+SoCExpansion (Investigational Arm 2): NIS793+TISLE+SoCExpansion (Control Arm): SoC (FOLFIRI)
(Expansion Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1NA (NA to NA)NA (NA to NA)NA (NA to NA)
Secondary(Expansion Part) Overall Survival (OS)

OS was defined as the time from the date of enrollment to the date of death due to any cause

Time frame:
Up to two years
Reported as:
Median · Months
(Expansion Part) Overall Survival (OS)
MonthsExpansion (Investigational Arm 1): NIS793+SoCExpansion (Investigational Arm 2): NIS793+TISLE+SoCExpansion (Control Arm): SoC
(Expansion Part) Overall Survival (OS)12.8 (8.0 to 14.2)10.9 (6.1 to NA)NA (11.6 to NA)
Secondary(Expansion Part) Maximum Concentration (Cmax) of NIS793 and Tislelizumab

Blood samples were collected at indicated time-points for analysis of Cmax of NIS793 and tislelizumab

Time frame:
Cycle 1 Day 1, Cycle 3 Day 1 (NIS793 only) (1 cycle = 28 days)
Reported as:
Mean · ng/mL
(Expansion Part) Maximum Concentration (Cmax) of NIS793 and Tislelizumab
ng/mLExpansion (Investigational Arm 1): NIS793 + SoCExpansion (Investigational Arm 2): NIS793 + Tislelizumab + SoC
NIS793: Cycle 1 Day 1598000 ± 178000694000 ± 478000
NIS793: Cycle 3 Day 1904000 ± 301000871000 ± 315000
tislelizumab: Cycle 1 Day 1—93400 ± NA
Secondary(Expansion Part) Trough Concentration (Ctrough) of NIS793 and Tislelizumab

Blood samples were collected at indicated time-points for analysis of Ctrough of NIS793 and tislelizumab

Time frame:
Cycle 1 Day 15 (NIS793 only), Cycle 2 Day (tislelizumab only), Cycle 3 Day 1, Cycle 3 Day 15 (NIS793 only), Cycle 4 Day (tislelizumab only), Cycle 6 Day 1 (NIS793 only) (1 cycle = 28 days)
Reported as:
Mean · ng/mL
(Expansion Part) Trough Concentration (Ctrough) of NIS793 and Tislelizumab
ng/mLExpansion (Investigational Arm 1): NIS793 + SoCExpansion (Investigational Arm 2): NIS793 + Tislelizumab + SoC
NIS793: Cycle 1 Day 15189000 ± 56200181000 ± 50000
NIS793: Cycle 3 Day 1371000 ± 1116000391000 ± 100000
NIS793: Cycle 3 Day 15394000 ± 121000342000 ± 186000
NIS793: Cycle 6 Day 1365000 ± 180000—
tislelizumab: Cycle 2 Day 1—25400 ± 19600
tislelizumab: Cycle 3 Day 1—29400 ± 12700
tislelizumab: Cycle 4 Day 1—39400 ± 17100
Secondary(Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) at Baseline

Prevalence of NIS793 and Tislelizumab Antidrug antibodies (ADA) at baseline was defined as the proportion of participants who had an ADA positive result at baseline

Time frame:
Baseline
Reported as:
Count of participants · Participants
(Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) at Baseline
ParticipantsExpansion (Investigational Arm 1): NIS793 + SoCExpansion (Investigational Arm 2): NIS793 + Tislelizumab + SoC
NIS793: ADA-positive (i.e. ADA prevalence)00
Tislelizumab: ADA-positive (i.e. ADA prevalence)01
Secondary(Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on Treatment

Incidence of NIS793 and Tislelizumab Antidrug antibodies (ADA) on treatment was defined as the proportion of participants who were treatment-induced ADA positive (post-baseline ADA positive with an ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with a titer that was at least the fold titer change greater than the ADA-positive baseline titer)

Time frame:
From the date of first study drug intake up to approximately 11 months
Reported as:
Count of participants · Participants
(Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on Treatment
ParticipantsExpansion (Investigational Arm 1): NIS793 + SoCExpansion (Investigational Arm 2): NIS793 + Tislelizumab + SoC
NIS793: Treatment-induced ADA-positive00
NIS793: Treatment-boosted ADA-positive00
Tislelizumab: Treatment-induced ADA-positive00
Tislelizumab: Treatment-boosted ADA-positive00

Adverse events

Collected over Adverse Events (AEs) were recorded from the first dose of study medication through 30 days after the last dose of Standard of Care, with assessments spanning approximately 38 months. The Safety Run-in phase averaged 162.5 days (about 5.4 months), while the Expansion phase averaged 221.3 days (about 7.4 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Run-In (Investigational Arm 1): NIS793+SoC(FOLFIRI)8/13 (61.5%)6/13 (46.2%)0/13 (0%)
Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6)5/9 (55.6%)6/9 (66.7%)0/9 (0%)
Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)8/10 (80%)6/10 (60%)0/10 (0%)
Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6)2/8 (25%)5/8 (62.5%)0/8 (0%)
Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI)33/65 (50.8%)32/65 (49.2%)0/65 (0%)
Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6)9/15 (60%)6/15 (40%)0/15 (0%)
Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)12/29 (41.4%)9/29 (31%)0/29 (0%)
Expansion (Control Arm): SoC (FOLFIRI)13/46 (28.3%)14/46 (30.4%)0/46 (0%)
Expansion (Control Arm): SoC (mFOLFOX6)3/7 (42.9%)3/7 (42.9%)0/7 (0%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventSafety Run-In (Investigational Arm 1): NIS793+SoC(FOLFIRI)Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6)Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI)Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Expansion (Control Arm): SoC (FOLFIRI)Expansion (Control Arm): SoC (mFOLFOX6)
PyrexiaGeneral disorders0/130/92/100/80/651/151/294/461/7
Myocardial infarctionCardiac disorders0/130/90/100/80/650/150/290/461/7
Infusion related reactionInjury, poisoning and procedural complications0/130/90/100/80/650/150/290/461/7
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/130/90/100/81/652/150/291/460/7
AnaemiaBlood and lymphatic system disorders0/130/90/101/83/650/151/290/460/7
Abdominal painGastrointestinal disorders0/130/90/101/81/650/150/291/460/7
DiarrhoeaGastrointestinal disorders0/130/91/101/84/650/152/292/460/7
VomitingGastrointestinal disorders0/130/90/101/81/650/150/290/460/7
Mucosal inflammationGeneral disorders0/130/90/101/80/650/150/290/460/7
CellulitisInfections and infestations0/130/90/101/80/650/150/290/460/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI)Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6)Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI)Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Expansion (Control Arm): SoC (FOLFIRI)Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Expansion (Control Arm): SoC (mFOLFOX6)Total
<=18 years0000000000
Between 18 and 65 years11665462436114149
>=65 years2343215102353
Sex: Female, Male
Sex: Female, Male(Participants)Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI)Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6)Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI)Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Expansion (Control Arm): SoC (FOLFIRI)Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Expansion (Control Arm): SoC (mFOLFOX6)Total
Female113222911188286
Male268638182855116
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Safety Run-In (Investigational Arm 1): NIS793+SoC (FOLFIRI)Safety Run-In (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Safety Run-In (Investigational Arm 2): NIS793+TISLE+SoC (mFOLFOX6)Expansion (Investigational Arm 1): NIS793+SoC (FOLFIRI)Expansion (Investigational Arm 2): NIS793+TISLE+SoC (FOLFIRI)Expansion (Control Arm): SoC (FOLFIRI)Expansion (Investigational Arm 1): NIS793+SoC (mFOLFOX6)Expansion (Control Arm): SoC (mFOLFOX6)Total
American Indian or Alaska Native0000000000
Asian2211155104040
Native Hawaiian or Other Pacific Islander0000000000
Black or African American1000121005
White1079750203497153
More than one race0000010001
Unknown or Not Reported0000111003
08

Study locations

55 sites
  • The Angeles Clinic and Research Institute
    Los Angeles, California 90025, United States
  • University of Michigan Medical
    Ann Arbor, Michigan 48109-0331, United States
  • WA Uni School Of Med
    St Louis, Missouri 63110, United States
  • Astera Cancer Center
    East Brunswick, New Jersey 08816, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Uni Of TX MD Anderson Cancer Cntr
    Houston, Texas 77030, United States
  • Mays Cancer Center
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Bendigo, Victoria 3550, Australia
  • Novartis Investigative Site
    Perth, Western Australia 6009, Australia
  • Novartis Investigative Site
    Brussels, 1000, Belgium
  • Novartis Investigative Site
    Brussels, 1200, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Brampton, Ontario L6R 3J7, Canada
  • Novartis Investigative Site
    Cambridge, Ontario N1R 3G2, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2X 1R9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3T 1E2, Canada
  • Novartis Investigative Site
    Brno, 656 53, Czechia
  • Novartis Investigative Site
    Hradec Králové, 500 05, Czechia
  • Novartis Investigative Site
    Prague, 140 59, Czechia
  • Novartis Investigative Site
    Avignon, 84082, France
  • Novartis Investigative Site
    Créteil, 94010, France
  • Novartis Investigative Site
    Nantes, 44093, France
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60488, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Hamburg, 20249, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Hong Kong, 999077, Hong Kong
  • Novartis Investigative Site
    Haifa, 3109601, Israel
  • Novartis Investigative Site
    Petah Tikva, 4941492, Israel
  • Novartis Investigative Site
    Milan, MI 20133, Italy
  • Novartis Investigative Site
    Milan, MI 20162, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Nagoya, Aichi-ken 4648681, Japan
  • Novartis Investigative Site
    Kashiwa, Chiba 2778577, Japan
  • Novartis Investigative Site
    Kawasaki, Kanagawa 2168511, Japan
  • Novartis Investigative Site
    Osaka, Osaka 5418567, Japan
  • Novartis Investigative Site
    Toyama, Toyama 9300194, Japan
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Seoul, 05505, South Korea
  • Novartis Investigative Site
    Sabadell, Barcelona 08208, Spain
  • Novartis Investigative Site
    Santander, Cantabria 39008, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Sankt Gallen, 9007, Switzerland
  • Novartis Investigative Site
    Tainan, 704302, Taiwan
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Aberdeen, Grampian Region AB25 2ZN, United Kingdom
  • Novartis Investigative Site
    Cambridge, CB2 0QQ, United Kingdom
  • Novartis Investigative Site
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jan 2025, 38 months.

Results were first posted in Nov 2026, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2021
First posted
Jul 7, 2021
StartActual
Nov 15, 2021
Primary completionActual
Jan 20, 2025
CompletionActual
Jan 20, 2025
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 16, 2026
Sites
20 sites added, 20 sites removed
Show 20 added (3 Czechia, 3 Japan, 2 Belgium, 2 France, 2 Germany, 2 Italy, 2 Spain, 1 United States, 1 Hong Kong, 1 Israel, 1 Switzerland)
  • WA Uni School Of Med · St Louis, United States
  • Novartis Investigative Site · Brussels, Belgium
  • Novartis Investigative Site · Brussels, Belgium
  • Novartis Investigative Site · Brno, Czechia
  • Novartis Investigative Site · Hradec Králové, Czechia
  • Novartis Investigative Site · Prague, Czechia
  • Novartis Investigative Site · Créteil, France
  • Novartis Investigative Site · Nantes, France
  • Novartis Investigative Site · Frankfurt am Main, Germany
  • Novartis Investigative Site · Dresden, Germany
  • Novartis Investigative Site · Hong Kong, Hong Kong
  • Novartis Investigative Site · Petah Tikva, Israel
  • Novartis Investigative Site · Milan, Italy
  • Novartis Investigative Site · Milan, Italy
  • Novartis Investigative Site · Nagoya, Japan
  • Novartis Investigative Site · Osaka, Japan
  • Novartis Investigative Site · Toyama, Japan
  • Novartis Investigative Site · Barcelona, Spain
  • Novartis Investigative Site · Barcelona, Spain
  • Novartis Investigative Site · Sankt Gallen, Switzerland
Show 20 removed
  • WA Uni School Of Med · Saint Louis, United States
  • Novartis Investigative Site · Bruxelles, Belgium
  • Novartis Investigative Site · Bruxelles, Belgium
  • Novartis Investigative Site · Brno, Czechia
  • Novartis Investigative Site · Hradec Kralove, Czechia
  • Novartis Investigative Site · Praha 4, Czechia
  • Novartis Investigative Site · Creteil, France
  • Novartis Investigative Site · Nantes Cedex 1, France
  • Novartis Investigative Site · Frankfurt am Main, Germany
  • Novartis Investigative Site · Pokfulam, Hong Kong
  • Novartis Investigative Site · Shatin, Hong Kong
  • Novartis Investigative Site · Petach Tikva, Israel
  • Novartis Investigative Site · Milano, Italy
  • Novartis Investigative Site · Milano, Italy
  • Novartis Investigative Site · Nagoya, Japan
  • Novartis Investigative Site · Osaka-city, Japan
  • Novartis Investigative Site · Toyama, Japan
  • Novartis Investigative Site · Barcelona, Spain
  • Novartis Investigative Site · Barcelona, Spain
  • Novartis Investigative Site · St Gallen, Switzerland
Nov 16, 2026
Enrollment
204→202
Nov 16, 2026
Eligibility
8 criteria edited, 1 added, 2 removed
What changed in the criteria
  • EditedParticipants ageaged 18 or older with histologically or cytologically confirmed (by local laboratory and local clinical guidelines) metastatic colorectal adenocarcinoma that is not amenable to potentially curative surgery in the opinion of the investigatorInvestigator and progressed on or within 6 months after the last dose of one prior line of systemic anti-cancer therapy administered for metastatic disease.
  • EditedEastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
  • ChangedBefore Previously administered TGF-β targeted therapies or anti-cancer immunotherapy.Now Previously administered systemic immunotherapy (e.g. anti-PD-1, anti-PD-L1/-L2, anti-CTLA-4 antibody) or TGF-β targeted therapies.
  • EditedMicrosatellite instability-high (MSI-H)/mismatch repair-deficient (dMMRmandatory, locally performed) and/or, BRAFV600 mutation positive colorectal cancerCRC.
  • ChangedBefore Known complete or partial dipyrimidine dehydrogenase (DPD) enzyme deficiency (testing for DPD enzyme deficiency is not mandatory unless required by local regulations and can be conducted at a local laboratory).Now Known complete or partial DPD enzyme deficiency.
  • EditedFor participants treated with irinotecan: Known history or clinical evidence of reduced UGT1A1 activity (testing for UGT1A1 status is not mandatory unless required by local regulations and can be conducted at a local laboratory).
  • EditedParticipants with conditions that are considered to have a high risk of clinically significant gastrointestinal tract bleeding or any other condition associated with or history of significant bleeding.
  • RemovedPregnant or breast-feeding women.
  • AddedActive, known, or suspected autoimmune disease or a documented history of autoimmune disease
  • EditedWomenPregnant or breast-feeding women, and women of childbearing potential, unless willing to use highly effective contraception methods during treatment and after stopping study treatments as required.
  • RemovedOther inclusion/exclusion criteria may apply
Nov 16, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • Edited(Safety run-in: Percentage Part) Number of participants with dose limiting toxicitiesParticipants With Dose Limiting Toxicities (DLTs) duringDuring the first cycleFirst Cycle (4 weeksWeeks) of treatmentTreatment.Time frame: Up to 4 weeks
  • Edited(Expansion: Part) Progression-free survivalSurvival (PFS) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: From randomization up to disease progression or death, assessed up to approximately 12 months → From randomization up to disease progression or death, assessed up to approximately 11 months
Nov 16, 2026
Documents
Secondary outcomes
22 edited, 3 added, 1 removed
What changed in the outcomes
  • Edited(Safety run-in: Part) Percentage of participants withParticipants With Adverse Events (AEs)Time frame: Up to approximately 12 months → Through Safety Run-in completion, an average of 6 months
  • Edited(Safety runRun-in:In) Percentage of participants with dose interruptionsParticipants With Dose Interruptions and dose reductionsDose Reductions of investigational drugInvestigational DrugTime frame: Upto approximately 12 months → Up to approximately 7 months
  • Edited(Safety runRun-in:In) Dose intensityIntensity of investigational drugInvestigational DrugTime frame: Up to approximately 12 months → Up to approximately 7 months
  • Edited(Safety run-in: Part) PFS by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: From enrollment up to disease progression or death, assessed up to approximately 12 months → From enrollment up to disease progression or death, assessed up to approximately 7 months
  • Edited(Safety run-in: Part) Overall response rateResponse Rate (ORR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: Up to approximately 12 months → Up to approximately 7 months
  • Edited(Safety run-in: Part) Disease control rateControl Rate (DCR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: Up to approximately 12 months → Up to approximately 7 months
  • Edited(Safety run-in: Part) Duration of responseResponse (DOR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: From first documented response up to disease progression or death, assessed up to approximately 12 months → From first documented response up to disease progression or death, assessed up to approximately 7 months
  • Edited(Safety run-in part:Part) Overall Survival (OS)Time frame: From enrollment up to death, assessed up to approximately 12 months → Up to two years
  • Edited(Safety run-in: Part) Time to responseResponse (TTR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: From enrollment up to first documented response, assessed up to approximately 12 months → From enrollment up to first documented response, assessed up to approximately 7 months
  • Edited(Expansion: Part) Percentage of participants withParticipants With Adverse Events (AEs)Time frame: Up to approximately 12 months → Through Expansion completion, an average of 8 months
  • Edited(Expansion part:Part) Percentage of participants with dose interruptionsParticipants With Dose Interruptions and dose reductionsDose Reductions of investigational drugInvestigational DrugTime frame: Up to approximately 12 months → Up to approximately 11 months
  • Edited(Expansion: Part) Dose intensityIntensity of investigational drugInvestigational DrugTime frame: Up to approximately 12 months → Up to approximately 11 months
  • Edited(Expansion: Part) Overall response rateResponse Rate (ORR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: Up to approximately 12 months → Up to approximately 11 months
  • Edited(Expansion: Part) Disease control rateControl Rate (DCR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: Up to approximately 12 months → Up to approximately 11 months
  • Edited(Expansion: Part) Duration of responseResponse (DOR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: From first documented response up to disease progression or death, assessed up to approximately 12 months → From first documented response up to disease progression or death, assessed up to approximately 11 months
  • Edited(Expansion part:Part) Overall Survival (OS)Time frame: From randomization up to death, assessed up to approximately 12 months → Up to two years
  • Edited(Expansion: Part) Time to responseResponse (TTR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: From enrollment up to first documented response, assessed up to approximately 12 months → From enrollment up to first documented response, assessed up to approximately 11 months
  • Edited(Safety run-in Part) Maximum concentrationConcentration (Cmax) of NIS793 and TislelizumabTime frame: From the date of first study drug intake up to approximately 12 months → Cycle 1 Day 1, Cycle 3 Day 1 (1 cycle = 28 days).
  • Edited(Expansion Part) Maximum concentrationConcentration (Cmax) of tislelizumabNIS793 and TislelizumabTime frame: From the date of first study drug intake up to approximately 12 months → Cycle 1 Day 1, Cycle 3 Day 1 (NIS793 only) (1 cycle = 28 days)
  • Edited(Safety run-in Part) Trough Concentration (Ctrough) of NIS793 and TislelizumabTime frame: From the date of first study drug intake up to approximately 12 months → Cycle 1 Day 15, Cycle 3 Day 1, Cycle 3 Day 15, Cycle 6 Day 1 (1 cycle = 28 days)
  • Edited(Expansion Part) Trough Concentration (Ctrough) tislelizumabof NIS793 and TislelizumabTime frame: From the date of first study drug intake up to approximately 12 months → Cycle 1 Day 15 (NIS793 only), Cycle 2 Day (tislelizumab only), Cycle 3 Day 1, Cycle 3 Day 15 (NIS793 only), Cycle 4 Day (tislelizumab only), Cycle 6 Day 1 (NIS793 only) (1 cycle = 28 days)
  • Edited(Safety run-in Part) NIS793 and Tislelizumab Antidrug antibodiesAntibodies (ADA) at baselineBaselineTime frame: Baseline
  • Added(Safety run-in Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on TreatmentTime frame: From the date of first study drug intake up to approximately 7 months
  • Added(Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) at BaselineTime frame: Baseline
  • Added(Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on TreatmentTime frame: From the date of first study drug intake up to approximately 11 months
  • RemovedADA incidence on treatmentTime frame: From the date of first study drug intake up to approximately 12 months
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Results posted
    20 sites added, 20 sites removed
    Show 20 added (3 Czechia, 3 Japan, 2 Belgium, 2 France, 2 Germany, 2 Italy, 2 Spain, 1 United States, 1 Hong Kong, 1 Israel, 1 Switzerland)
    • WA Uni School Of Med · St Louis, United States
    • Novartis Investigative Site · Brussels, Belgium
    • Novartis Investigative Site · Brussels, Belgium
    • Novartis Investigative Site · Brno, Czechia
    • Novartis Investigative Site · Hradec Králové, Czechia
    • Novartis Investigative Site · Prague, Czechia
    • Novartis Investigative Site · Créteil, France
    • Novartis Investigative Site · Nantes, France
    • Novartis Investigative Site · Frankfurt am Main, Germany
    • Novartis Investigative Site · Dresden, Germany
    • Novartis Investigative Site · Hong Kong, Hong Kong
    • Novartis Investigative Site · Petah Tikva, Israel
    • Novartis Investigative Site · Milan, Italy
    • Novartis Investigative Site · Milan, Italy
    • Novartis Investigative Site · Nagoya, Japan
    • Novartis Investigative Site · Osaka, Japan
    • Novartis Investigative Site · Toyama, Japan
    • Novartis Investigative Site · Barcelona, Spain
    • Novartis Investigative Site · Barcelona, Spain
    • Novartis Investigative Site · Sankt Gallen, Switzerland
    Show 20 removed
    • WA Uni School Of Med · Saint Louis, United States
    • Novartis Investigative Site · Bruxelles, Belgium
    • Novartis Investigative Site · Bruxelles, Belgium
    • Novartis Investigative Site · Brno, Czechia
    • Novartis Investigative Site · Hradec Kralove, Czechia
    • Novartis Investigative Site · Praha 4, Czechia
    • Novartis Investigative Site · Creteil, France
    • Novartis Investigative Site · Nantes Cedex 1, France
    • Novartis Investigative Site · Frankfurt am Main, Germany
    • Novartis Investigative Site · Pokfulam, Hong Kong
    • Novartis Investigative Site · Shatin, Hong Kong
    • Novartis Investigative Site · Petach Tikva, Israel
    • Novartis Investigative Site · Milano, Italy
    • Novartis Investigative Site · Milano, Italy
    • Novartis Investigative Site · Nagoya, Japan
    • Novartis Investigative Site · Osaka-city, Japan
    • Novartis Investigative Site · Toyama, Japan
    • Novartis Investigative Site · Barcelona, Spain
    • Novartis Investigative Site · Barcelona, Spain
    • Novartis Investigative Site · St Gallen, Switzerland
    Enrollment 204→202
    Eligibility 8 criteria edited, 1 added, 2 removed
    What changed in the criteria
    • EditedParticipants ageaged 18 or older with histologically or cytologically confirmed (by local laboratory and local clinical guidelines) metastatic colorectal adenocarcinoma that is not amenable to potentially curative surgery in the opinion of the investigatorInvestigator and progressed on or within 6 months after the last dose of one prior line of systemic anti-cancer therapy administered for metastatic disease.
    • EditedEastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
    • ChangedBefore Previously administered TGF-β targeted therapies or anti-cancer immunotherapy.Now Previously administered systemic immunotherapy (e.g. anti-PD-1, anti-PD-L1/-L2, anti-CTLA-4 antibody) or TGF-β targeted therapies.
    • EditedMicrosatellite instability-high (MSI-H)/mismatch repair-deficient (dMMRmandatory, locally performed) and/or, BRAFV600 mutation positive colorectal cancerCRC.
    • ChangedBefore Known complete or partial dipyrimidine dehydrogenase (DPD) enzyme deficiency (testing for DPD enzyme deficiency is not mandatory unless required by local regulations and can be conducted at a local laboratory).Now Known complete or partial DPD enzyme deficiency.
    • EditedFor participants treated with irinotecan: Known history or clinical evidence of reduced UGT1A1 activity (testing for UGT1A1 status is not mandatory unless required by local regulations and can be conducted at a local laboratory).
    • EditedParticipants with conditions that are considered to have a high risk of clinically significant gastrointestinal tract bleeding or any other condition associated with or history of significant bleeding.
    • RemovedPregnant or breast-feeding women.
    • AddedActive, known, or suspected autoimmune disease or a documented history of autoimmune disease
    • EditedWomenPregnant or breast-feeding women, and women of childbearing potential, unless willing to use highly effective contraception methods during treatment and after stopping study treatments as required.
    • RemovedOther inclusion/exclusion criteria may apply
    Primary outcomes 2 edited
    What changed in the outcomes
    • Edited(Safety run-in: Percentage Part) Number of participants with dose limiting toxicitiesParticipants With Dose Limiting Toxicities (DLTs) duringDuring the first cycleFirst Cycle (4 weeksWeeks) of treatmentTreatment.Time frame: Up to 4 weeks
    • Edited(Expansion: Part) Progression-free survivalSurvival (PFS) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: From randomization up to disease progression or death, assessed up to approximately 12 months → From randomization up to disease progression or death, assessed up to approximately 11 months
    Secondary outcomes 22 edited, 3 added, 1 removed
    What changed in the outcomes
    • Edited(Safety run-in: Part) Percentage of participants withParticipants With Adverse Events (AEs)Time frame: Up to approximately 12 months → Through Safety Run-in completion, an average of 6 months
    • Edited(Safety runRun-in:In) Percentage of participants with dose interruptionsParticipants With Dose Interruptions and dose reductionsDose Reductions of investigational drugInvestigational DrugTime frame: Upto approximately 12 months → Up to approximately 7 months
    • Edited(Safety runRun-in:In) Dose intensityIntensity of investigational drugInvestigational DrugTime frame: Up to approximately 12 months → Up to approximately 7 months
    • Edited(Safety run-in: Part) PFS by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: From enrollment up to disease progression or death, assessed up to approximately 12 months → From enrollment up to disease progression or death, assessed up to approximately 7 months
    • Edited(Safety run-in: Part) Overall response rateResponse Rate (ORR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: Up to approximately 12 months → Up to approximately 7 months
    • Edited(Safety run-in: Part) Disease control rateControl Rate (DCR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: Up to approximately 12 months → Up to approximately 7 months
    • Edited(Safety run-in: Part) Duration of responseResponse (DOR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: From first documented response up to disease progression or death, assessed up to approximately 12 months → From first documented response up to disease progression or death, assessed up to approximately 7 months
    • Edited(Safety run-in part:Part) Overall Survival (OS)Time frame: From enrollment up to death, assessed up to approximately 12 months → Up to two years
    • Edited(Safety run-in: Part) Time to responseResponse (TTR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: From enrollment up to first documented response, assessed up to approximately 12 months → From enrollment up to first documented response, assessed up to approximately 7 months
    • Edited(Expansion: Part) Percentage of participants withParticipants With Adverse Events (AEs)Time frame: Up to approximately 12 months → Through Expansion completion, an average of 8 months
    • Edited(Expansion part:Part) Percentage of participants with dose interruptionsParticipants With Dose Interruptions and dose reductionsDose Reductions of investigational drugInvestigational DrugTime frame: Up to approximately 12 months → Up to approximately 11 months
    • Edited(Expansion: Part) Dose intensityIntensity of investigational drugInvestigational DrugTime frame: Up to approximately 12 months → Up to approximately 11 months
    • Edited(Expansion: Part) Overall response rateResponse Rate (ORR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: Up to approximately 12 months → Up to approximately 11 months
    • Edited(Expansion: Part) Disease control rateControl Rate (DCR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: Up to approximately 12 months → Up to approximately 11 months
    • Edited(Expansion: Part) Duration of responseResponse (DOR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: From first documented response up to disease progression or death, assessed up to approximately 12 months → From first documented response up to disease progression or death, assessed up to approximately 11 months
    • Edited(Expansion part:Part) Overall Survival (OS)Time frame: From randomization up to death, assessed up to approximately 12 months → Up to two years
    • Edited(Expansion: Part) Time to responseResponse (TTR) by investigator assessment perInvestigator Assessment Per RECIST 1.1Time frame: From enrollment up to first documented response, assessed up to approximately 12 months → From enrollment up to first documented response, assessed up to approximately 11 months
    • Edited(Safety run-in Part) Maximum concentrationConcentration (Cmax) of NIS793 and TislelizumabTime frame: From the date of first study drug intake up to approximately 12 months → Cycle 1 Day 1, Cycle 3 Day 1 (1 cycle = 28 days).
    • Edited(Expansion Part) Maximum concentrationConcentration (Cmax) of tislelizumabNIS793 and TislelizumabTime frame: From the date of first study drug intake up to approximately 12 months → Cycle 1 Day 1, Cycle 3 Day 1 (NIS793 only) (1 cycle = 28 days)
    • Edited(Safety run-in Part) Trough Concentration (Ctrough) of NIS793 and TislelizumabTime frame: From the date of first study drug intake up to approximately 12 months → Cycle 1 Day 15, Cycle 3 Day 1, Cycle 3 Day 15, Cycle 6 Day 1 (1 cycle = 28 days)
    • Edited(Expansion Part) Trough Concentration (Ctrough) tislelizumabof NIS793 and TislelizumabTime frame: From the date of first study drug intake up to approximately 12 months → Cycle 1 Day 15 (NIS793 only), Cycle 2 Day (tislelizumab only), Cycle 3 Day 1, Cycle 3 Day 15 (NIS793 only), Cycle 4 Day (tislelizumab only), Cycle 6 Day 1 (NIS793 only) (1 cycle = 28 days)
    • Edited(Safety run-in Part) NIS793 and Tislelizumab Antidrug antibodiesAntibodies (ADA) at baselineBaselineTime frame: Baseline
    • Added(Safety run-in Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on TreatmentTime frame: From the date of first study drug intake up to approximately 7 months
    • Added(Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) at BaselineTime frame: Baseline
    • Added(Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on TreatmentTime frame: From the date of first study drug intake up to approximately 11 months
    • RemovedADA incidence on treatmentTime frame: From the date of first study drug intake up to approximately 12 months
    + 5 other changes: index terms, identifiers, verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04952753
Responsible party
Sponsor
First posted
Jul 7, 2021
Start date
Nov 15, 2021
Primary completion
Jan 20, 2025
Completion
Jan 20, 2025
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nisevokitug

Start the discussion